- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04242940
Assessing Listening Effort at Different Signal-to-noise Ratios in Bone-anchored Users
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B15 2TH
- Audiology Department, Nuffield House, University Hospitals Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Minimum 18 years and maximum 70 years old.
- UK English mother tongue.
- Bilateral conductive or mixed hearing loss.
- Users fitted unilaterally or bilaterally on abutment.
- Users are currently fitted with either Ponto 3, Ponto Plus or Ponto Pro (devices with a fitting range up to 45 dB HL).
- Users with at least 6 months of daily experience with one Ponto sound processor.
- BC thresholds of the implanted ear(s) better (lower) than or equal to 40 dB HL (average of 0.5, 1, 2 and 3 kHz) based on BC in-situ measurement at the first visit.
- People currently employed/self-employed (since the Need for Recovery questionnaire refers to work-related fatigue).
- Speech recognition scores better (higher) than or equal to 50% at +4 dB SNR with OSN OFF (as assessed via the first training list at Visit 1). This is to avoid including patients that are already "giving up" at +4 dB SNR.
- Users entitled for a sound-processor upgrade (according to the investigator) will first be selected. If there are not enough users entitled for an upgrade, then patients fitted with Ponto between 7 and 12 months before visit 1 will be considered. If there are not enough users within 7-12 months, then patients fitted with Ponto between 13 and 18 months before visit 1 will be considered.
Exclusion Criteria:
- Single-sided deafness (SSD)
- Hearing aid or cochlear implant on the opposite ear.
- Test persons with current eye diseases and/or history of eye surgery on both eyes.
- If the patient takes medications that can impact the autonomic nervous system - and hence pupil dilation (e.g., drugs for Parkinson's disease, peptic ulcers, incontinence, motion sickness).
- If the investigator or physician assesses that the patient is not fit for trial participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Ponto 4 sound processor
All patients will be fitted with a bone-anchored sound processor (Ponto 4), unilaterally or bilaterally.
|
Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction.
The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea).
Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear.
The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Pupil Dilation
Time Frame: 10 days
|
Overall pupil dilation for OSN ON and OSN OFF at +4 dB SNR a third-order polynomial function was fit to the pupil dilation data, with the OSN setting as a fixed factor, as well as the interaction of OSN with each of the polynomial time terms. The formula used is the following: Pupil Dilation = (Linear + Quadratic + Cubic) X OSN setting + (1 + Linear + Quadratic + Cubic| Subject); where the Linear, Quadratic, and Cubic are the orthogonal terms; X indicates the interaction with OSN setting, and the terms reported in the second parenthesis are the random factors. The random factors include the effect of listeners, and of each of the time terms, to account for the variability in the time course of dilation across listeners. Outcome measure is the percentage reduction(% change) in pupil dilation with OSN ON vs OSN OFF |
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak Pupil Dilation (PPD) for OSN ON and OSN OFF
Time Frame: 10 days
|
The difference in pupil dilation between OSN ON and OSN OFF was also analyzed via Peak Pupil Dilation (PPD); thus, by investigating differences in dilation at the peak of the curve.
The PPD was obtained for each subject as the maximum dilation between 7.5 and 9 s.
|
10 days
|
|
Speech Recognition Scores With OSN ON vs. OSN OFF Across SNRs
Time Frame: 10 days
|
A mixed-linear model with OSN setting (2 levels: ON and OFF) and SNR (5 levels: -8, -4, 0, +4, +8 dB) as fixed factors, and subject as random factor, was fit to the data.
|
10 days
|
|
Speech Spatial and Qualities of Hearing Scale (SSQ) Questionnaire Scores
Time Frame: 4 months
|
Self-reported perception before, during (at 1 month), and after field trial (at 3months). The SSQ questionnaire consists of 49 items with a scale from 0-10 where 0 represents "Not at all" and 10 represents "Perfect". The SSQ questionnaire is comprised of three subscales domains (Speech, Spatial, and Qualities of Hearing) - that is, each of the 49 items fits into one of these subscale "categories". The subscale scores AND the total scores (the total score is comprised of all of the 49 items) use the same scale of 0 to 10 where 0 represents "Not at all" and 10 represents "Perfect". For the total scale and all subscales (again all questions and by extension, the scales range from 0 to 10) the higher the value (closer to 10) represents a better outcome than lower values (closer to 0). |
4 months
|
|
Preference Questionnaire Scores.
Time Frame: 4 months
|
Self-reported preference after field trial.
The preference questionnaire consists of 11 questions.
The scores are from 1 to 5, where 1 means "Own sound processor much better" and 5 means "Test sound processor [Ponto 4] much better".
|
4 months
|
|
Aided Sound Field Thresholds
Time Frame: 4 months
|
Sound field audiometry performed with the Auricle system while the patient is wearing the Ponto sound processor.
This measurement is conducted at 10 frequencies from 250 Hz to 8 kHz.
The Pure tone threshold is calculated as the average across .5, 1, 2, & 3 kHz)
|
4 months
|
|
BC in Situ Thresholds.
Time Frame: 1 hour
|
Hearing level thresholds (dB HL) as assessed in situ with Ponto 4 placed on the patient's abutment.
Bone-conduction thresholds (BC) are measured as the softest sound level that is audible by the patient at 10 frequencies from 250 Hz to 8 kHz.
The Pure tone threshold is calculated as the average across .5, 1, 2, & 3 kHz
|
1 hour
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Need for Recovery (NFR) Questionnaire Scores.
Time Frame: 4 months
|
Self-reported work-related fatigue.
The NFR scale is an 11-item scale assessing the effects of fatigue caused by work (e.g., " I find it hard to relax at the end of a working day").
Possible responses are "yes" or "no".
The total NFR score is the number of "yes" responses divided by the total number of items, presented as a percentage (i.e., range 0-100).
The higher the score, the greater the NfR felt by the respondent.
Scores with own device compared with Ponto 4 after 3months field trial are reported.
|
4 months
|
|
Pupil Dilation After Field Trial.
Time Frame: 4 months
|
Change in pupil dilation after field trial to check for acclimatization effects.
Comparison of speech recognition scores for OSN Auto and OSN OFF at start and end of field trial.
|
4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: William Brassington, University Hospitals Birmingham, United Kingdom
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BC103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bilateral Hearing Loss
-
University Hospital Hradec KraloveThe Society of General Practice, J. E. Purkyne Czech Medical Association; Hospital...Enrolling by invitationHearing Loss, Bilateral or Unilateral | Hearing Loss, Bilateral Sensorineural, Progressive | Presbyacusis | Hearing Loss, Bilateral (Causes Other Than Tumors)Czechia
-
Nantes University HospitalRecruitingProfound Bilateral Hearing LossFrance
-
Massachusetts Eye and Ear InfirmaryTerminatedBilateral Hearing Loss for Causes Other Than TumorsUnited States
-
MED-EL Elektromedizinische Geräte GesmbHRecruitingSensorineural Hearing Loss, Bilateral | Bilateral Hearing LossFrance
-
Massachusetts Eye and Ear InfirmaryTerminatedBilateral Hearing Loss for Causes Other Than TumorsUnited States
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
CochlearVanderbilt University; NAMSA; AvaniaCompletedSensorineural Hearing Loss | Bilateral Hearing LossUnited States, Australia, New Zealand
-
MED-EL Elektromedizinische Geräte GesmbHCompletedSensorineural Hearing Loss, BilateralFrance
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
MED-EL Elektromedizinische Geräte GesmbHCompletedSensorineural Hearing Loss, BilateralFrance
Clinical Trials on Fitting of Ponto 4
-
Oticon MedicalCompleted
-
Oticon MedicalCompletedEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
Whisper.aiSan Jose State UniversityRecruitingHearing LossUnited States
-
WSAUD A/SUniversity of South DakotaCompleted
-
MED-EL Elektromedizinische Geräte GesmbHRecruitingSensorineural Hearing Loss, BilateralFrance
-
Centre Hospitalier Universitaire de NīmesCompleted
-
KK Women's and Children's HospitalActive, not recruitingHypertension, Pregnancy-InducedSingapore
-
Cambridge University Hospitals NHS Foundation TrustAdvanced Bionics AGCompletedHearing Loss, Bilateral | Cochlear Implant | Hearing Loss, Cochlear | Severe-Profound Hearing LossUnited Kingdom
-
Samsung Medical CenterCompleted
-
Hospital Universitario La PazMED-EL Elektromedizinische Geräte GesmbHRecruitingQuality of Life | Hearing Loss, Mixed | Bone Conduction DeafnessSpain